Lyme disease

Clinics in Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 311-328

  Murray, Thomas S ^a   Shapiro, Eugene D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borrellia burdorferi; Erythema migrans; Lyme disease; Misdiagnosis; Serologic testing; Tick borne infections

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; DIETHYLTOLUAMIDE; DOXYCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PLACEBO;

BACTERIAL MENINGITIS; BACTERIAL TRANSMISSION; BACTERIUM CARRIER; BACTERIUM CULTURE; BORRELIA BURGDORFERI; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HERXHEIMER REACTION; HUMAN; HUMORAL IMMUNITY; INCIDENCE; IXODES; LABORATORY TEST; LYME DISEASE; MEDICAL EXAMINATION; MYOCARDITIS; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROLOGY; SINGLE DRUG DOSE; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; BORRELIA BURGDORFERI; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; HUMANS; IXODES; LYME DISEASE; PEROMYSCUS; PROGNOSIS;

EID: 77953329728     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.01.003     Document Type: Review

References (62)

1. Shapiro E.D., Gerber M.A. Lyme disease. Clin Infect Dis 2000, 31(2):533-542.
2. Centers for Disease Control and Prevention Lyme disease - United States 2001-2002. MMWR Morb Mortal Wkly Rep 2004, 53:365-369.
3. Steere A.C., Taylor E., McHugh G.L., et al. The overdiagnosis of Lyme disease. JAMA 1993, 269(14):1812-1816.
4. Reid M.C., Schoen R.T., Evans J., et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998, 128(5):354-362.
5. Nadelman R.B., Nowakowski J., Fish D., et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001, 345(2):79-84.
6. Ullmann A.J., Lane R.S., Kurtenbach K., et al. Bacteriolytic activity of selected vertebrate sera for Borrelia burgdorferi sensu stricto and Borrelia bissettii. J Parasitol 2003, 89(6):1256-1257.
7. Rauter C., Hartung T. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol 2005, 71(11):7203-7216.
8. Piesman J., Mather T.N., Sinsky R.J., et al. Duration of tick attachment and Borrelia burgdorferi transmission. J Clin Microbiol 1987, 25(3):557-558.
9. Steere A.C. Lyme disease. N Engl J Med 2001, 345(2):115-125.
10. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(9):1089-1134.
11. Nadelman R.B., Wormser G.P. Lyme borreliosis. Lancet 1998, 352(9127):557-565.
12. Gerber M.A., Shapiro E.D., Burke G.S., et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 1996, 335(17):1270-1274.
13. Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998, 339(4):209-215.
14. Thompson A., Mannix R., Bachur R. Acute pediatric monoarticular arthritis; distinguishing Lyme arthritis from other etiologies. Pediatrics 2009, 123:959-965.
15. Schlesinger P.A., Duray P.H., Burke B.A., et al. Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann Intern Med 1985, 103(1):67-68.
16. Cartter M.L., Hadler J.L., Gerber M.A., et al. Lyme disease and pregnancy. Conn Med 1989, 53(6):341-342.
17. Silver H.M. Lyme disease during pregnancy. Infect Dis Clin North Am 1997, 11(1):93-97.
18. Strobino B.A., Williams C.L., Abid S., et al. Lyme disease and pregnancy outcome: a prospective study of two thousand prenatal patients. Am J Obstet Gynecol 1993, 169(2 Pt 1):367-374.
19. Gerber M.A., Zalneraitis E.L. Childhood neurologic disorders and Lyme disease during pregnancy. Pediatr Neurol 1994, 11(1):41-43.
20. Tilly K., Rosa P.A., Stewart P.E. Biology of infection with Borrelia burgdorferi. Infect Dis Clin North Am 2008, 22:217-234.
21. Hovius J.W., van Dam A.P., Fikrig E. Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol 2007, 23(9):434-438.
22. Coleman J.L., Gebbia J.A., Piesman J., et al. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997, 89(7):1111-1119.
23. Mullegger R.R., McHugh G., Ruthazer R., et al. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 2000, 115(6):1115-1123.
24. Fikrig E., Feng W., Aversa J., et al. Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis. J Infect Dis 1998, 178(4):1198-1201.
25. Krause A., Brade V., Schoerner C., et al. T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum 1991, 34(4):393-402.
26. Coburn J., Leong J.M., Erban J.K. Integrin alpha IIb beta 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci U S A 1993, 90(15):7059-7063.
27. Coburn J., Magoun L., Bodary S.C., et al. Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of Lyme disease spirochetes to human cells. Infect Immun 1998, 66(5):1946-1952.
28. Behera A.K., Durand E., Cugini C., et al. Borrelia burgdorferi BBB07 interaction with integrin alpha3beta1 stimulates production of pro-inflammatory mediators in primary human chondrocytes. Cell Microbiol 2008, 10(2):320-331.
29. Guo B.P., Brown E.L., Dorward D.W., et al. Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 1998, 30(4):711-723.
30. Probert W.S., Johnson B.J. Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31. Mol Microbiol 1998, 30(5):1003-1015.
31. Weis J.J., McCracken B.A., Ma Y., et al. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease. J Immunol 1999, 162(2):948-956.
32. Barthold S.W., de Souza M. Exacerbation of Lyme arthritis in beige mice. J Infect Dis 1995, 172(3):778-784.
33. Wooten R.M., Ma Y., Yoder R.A., et al. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002, 168(1):348-355.
34. Liu N., Montgomery R.R., Barthold S.W., et al. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice. Infect Immun 2004, 72(6):3195-3203.
35. Kelleher Doyle M., Telford S.R., Criscione L., et al. Cytokines in murine Lyme carditis: Th1 cytokine expression follows expression of proinflammatory cytokines in a susceptible mouse strain. J Infect Dis 1998, 177(1):242-246.
36. Barthold S.W., Feng S., Bockenstedt L.K., et al. Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi. Clin Infect Dis 1997, 25(Suppl 1):S9-S17.
37. Roberts E.D., Bohm R.P., Lowrie R.C., et al. Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: the early disseminated and chronic phases of disease in the peripheral nervous system. J Infect Dis 1998, 178(3):722-732.
38. Cadavid D., O'Neill T., Schaefer H., et al. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease. Lab Invest 2000, 80(7):1043-1054.
39. Steere A.C., Duray P.H., Butcher E.C. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988, 31(4):487-495.
40. Akin E., McHugh G.L., Flavell R.A., et al. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect Immun 1999, 67(1):173-181.
41. Vincent M.S., Roessner K., Sellati T., et al. Lyme arthritis synovial gamma delta T cells respond to Borrelia burgdorferi lipoproteins and lipidated hexapeptides. J Immunol 1998, 161(10):5762-5771.
42. Chen J., Field J.A., Glickstein L., et al. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum 1999, 42(9):1813-1822.
43. Gross D.M., Steere A.C., Huber B.T. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 1998, 160(2):1022-1028.
44. Yin Z., Braun J., Neure L., et al. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum 1997, 40(1):69-79.
45. Dressler F., Whalen J.A., Reinhardt B.N., et al. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993, 167(2):392-400.
46. Steere A.C., Levin R.E., Molloy P.J., et al. Treatment of Lyme arthritis. Arthritis Rheum 1994, 37(6):878-888.
47. Steere A.C., Klitz W., Drouin E.E., et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006, 203(4):961-971.
48. Shapiro E.D. Lyme disease in children. Am J Med 1995, 98(4A):69S-73S.
49. Centers for Disease Control and Prevention Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995, 44:590-591.
50. Seltzer E.G., Shapiro E.D. Misdiagnosis of Lyme disease: when not to order serologic tests. Pediatr Infect Dis J 1996, 15(9):762-763.
51. Tugwell P., Dennis D.T., Weinstein A., et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997, 127(12):1109-1123.
52. Steere A.C., Sikand V.K. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003, 348(24):2472-2474.
53. Feder H.M., Gerber M.A., Luger S.W., et al. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992, 15(5):788-793.
54. Kalish R.A., McHugh G., Granquist J., et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001, 33(6):780-785.
55. Ljostad U., Skogvoll E., Eikeland R., et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008, 7(8):690-695.
56. Mullegger R.R., Millner M.M., Stanek G., et al. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children - a prospective study. Infection 1991, 19(4):279-283.
57. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001, 345(2):85-92.
58. Ettestad P.J., Campbell G.L., Welbel S.F., et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995, 171(2):356-361.
59. Feder H.M., Johnson B.J., O'Connell S., et al. A critical appraisal of " chronic Lyme disease" N Engl J Med 2007, 357(14):1422-1430.
60. Vazquez M., Muehlenbein C., Cartter M., et al. Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis 2008, 14(2):210-216.
61. Brei B., Brownstein J.S., George J.E., et al. Evaluation of the United States Department of Agriculture Northeast Area-wide Tick Control Project by meta-analysis. Vector Borne Zoonotic Dis 2009, 9(4):423-430.
62. Shapiro E.D. Doxycycline for tick bites - not for everyone. N Engl J Med 2001, 345(2):133-134.